Resultados de la búsqueda 71-80 of 4722 for random glucose

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... randomized to receive inotuzumab. Other aims of this study include ... Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... randomized to receive inotuzumab. Other aims of this study include ... Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with MIBG-avid, ALK wild type (or ALK unknown) disease will be randomized to one of three arms: A) current COG recommended high-risk therapy ...